Evaluation and testing services (ETS) for vaccines and other biologics for infectious diseases

The Department of Health and Human Services, National Institutes of Health (NIH) is seeking to recompete a contract for "Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases." The purpose is to provide a suite of preclinical, non-clinical, and clinical testing services for a diverse collection of vaccine and biological product candidates. The contract will be an Indefinite Delivery/Indefinite Quantity (IDIQ) with a 7-year ordering period anticipated to start in August 2025. The work will be divided into four task areas: Administrative and Management Support Activities, Assay Development and Sample Testing, Non-clinical Immunogenicity and Efficacy Testing, and Safety and Toxicity Testing. Interested small businesses are required to submit capability statements addressing their expertise, facilities, and experience no later than April 22, 2024. The government plans to award multiple IDIQ contracts to the organizations best qualified to fulfill the technical requirements.

This is an unrestricted procurement with no set-aside designation. The current incumbent contractor is not named. While the total contract value is not specified, the intent is to provide individual testing services on a case-by-case basis for a diverse collection of vaccine and biological product candidates, rather than carry a single product candidate through an entire preclinical development pathway. The services are intended to support a wide variety of investigators in a broad number of scientific areas.